# Retatrutide

> Investigational triple receptor agonist with published phase 3 trials. Not approved by FDA, EMA, the MHRA or the TGA, the four regulators checked.

Source page: https://peptioresearch.com/peptides/retatrutide/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-23

## At a glance

- Research status: In clinical trials
- Also known as: LY3437943, LY-3437943
- Identifiers: CAS 2381089-83-2; PubChem CID 171390338; INN retatrutide
- Molecular weight: 4731

## What the research shows

Each claim is labelled with the strongest kind of study that supports it, which way the evidence points, and how confident that reading is.

### In a phase 3 trial of 2339 adults with obesity and without diabetes, body weight fell more with retatrutide than with placebo over 80 weeks.

- Evidence: Human randomised trial. Supportive. High confidence.
- Sources: [1][2]

TRIUMPH-1 randomised 2339 adults with obesity and without diabetes to retatrutide at 4 mg, 9 mg or 12 mg, or to placebo, for 80 weeks. Under the treatment-regimen estimand, which the paper equates with intention-to-treat, mean body weight changed by -17.6%, -23.7% and -25.0% in the three arms against -3.9% with placebo, differences of -19.8 and -21.0 percentage points for the 9 mg and 12 mg arms. An earlier phase 2 trial in 338 adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, and without diabetes, reported -24.2% in its 12 mg arm against -2.1% with placebo at 48 weeks, in the same direction.

Caveats:
- The figures come from the published abstracts only. The full texts were not available when this page was written.
- Both trials were funded by Eli Lilly, the developer.
- The results describe Lilly's investigational product given under trial conditions, not any product sold outside a trial.
- The TRIUMPH-1 abstract states the difference from placebo only for the 9 mg and 12 mg arms, and gives no adverse event frequencies or discontinuation rate.
- The phase 2 figures are least-squares means and that abstract names no estimand, so they are not directly comparable with the phase 3 figures.
- 80 weeks is the longest treatment period published. What happens to weight beyond it is not known from these trials.

### In a phase 3 trial of 1152 adults with type 2 diabetes and a BMI of 27 or higher, body weight fell more with retatrutide than with placebo over 80 weeks.

- Evidence: Human randomised trial. Supportive. High confidence.
- Sources: [3]

TRIUMPH-2 randomised 1152 adults with type 2 diabetes and a BMI of 27 or higher, at 92 centres in eight countries, to retatrutide at 4 mg, 9 mg or 12 mg, or to placebo. Under the treatment-regimen estimand, mean body weight at week 80 changed by -11.9% with 4 mg, -16.8% with 9 mg and -18.8% with 12 mg, against -5.1% with placebo. The estimated differences from placebo were -6.9, -11.8 and -13.8 percentage points.

Caveats:
- The figures come from the published abstract only. The full text was not available when this page was written.
- The trial was funded by Eli Lilly, the developer.
- The results describe Lilly's investigational product given under trial conditions, not any product sold outside a trial.
- 965 of the 1152 participants (84%) completed the study drug, and missing data were imputed.
- The abstract gives no efficacy-estimand result and no HbA1c figure; it says only that the drug was associated with improvements in glycaemic control.

### In a phase 3 trial of 537 adults with type 2 diabetes managed by diet and exercise alone, HbA1c fell more with retatrutide than with placebo over 40 weeks.

- Evidence: Human randomised trial. Supportive. High confidence.
- Sources: [4][5]

TRANSCEND-T2D-1 randomised 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone, with glycated haemoglobin (HbA1c) between 7.0% and 9.5%, at 48 sites in the USA, Mexico and India. Under the treatment-regimen estimand, mean HbA1c changed by -1.69% with 4 mg, -1.86% with 9 mg and -1.94% with 12 mg against -0.81% with placebo, differences of -0.88, -1.04 and -1.12 percentage points. An earlier phase 2 trial randomised 281 adults with type 2 diabetes treated with diet and exercise alone or with a stable dose of metformin; among the 275 in its efficacy analysis, HbA1c changed by -2.02% at 24 weeks in the 12 mg arm against -0.01% with placebo and -1.41% with dulaglutide 1.5 mg.

Caveats:
- The figures come from the published abstracts only. The full texts were not available when this page was written.
- Both trials were funded by Eli Lilly, the developer.
- The results describe Lilly's investigational product given under trial conditions, not any product sold outside a trial.
- Participants in the phase 3 trial had had diabetes for a mean of 2.5 years and were managing it with diet and exercise alone, so the result does not directly describe people already taking other diabetes medicines.
- HbA1c and body weight were the stated endpoints. The abstract reports no outcomes for diabetes complications.
- The phase 2 trial also enrolled people taking metformin, so its population is wider than the phase 3 trial's.
- The phase 2 figures are least-squares means and that abstract names no estimand.

### Within TRIUMPH-1, knee osteoarthritis pain and the apnoea-hypopnoea index in obstructive sleep apnoea both fell more with retatrutide than with placebo in subgroups of participants with those conditions.

- Evidence: Human randomised trial. Supportive. Moderate confidence.
- Sources: [1]

In the 574 participants with knee osteoarthritis, WOMAC pain, on a scale the abstract describes as ranging from 1 to 10, changed by -3.2, -3.5 and -3.6 points in the 4 mg, 9 mg and 12 mg arms against -1.9 with placebo under the hybrid estimand the paper applied (differences -1.6 and -1.8 for 9 mg and 12 mg), and by -3.4, -3.9 and -4.1 against -2.5 under intention-to-treat (differences -1.4 and -1.6). In the 243 participants with obstructive sleep apnoea, the apnoea-hypopnoea index, counted in events per hour, changed by -22.8, -34.3 and -32.1 against -9.6 with placebo under intention-to-treat (differences -24.7 and -22.5 for 9 mg and 12 mg). Under the hybrid estimand the stated differences were -24.4 and -21.9, against a placebo change of -9.9.

Caveats:
- The figures come from the published abstract only. The full text was not available when this page was written.
- The trial was funded by Eli Lilly, the developer.
- The results describe Lilly's investigational product given under trial conditions, not any product sold outside a trial.
- These were pre-specified primary outcomes, but in subgroups of 574 and 243 participants within one obesity trial. TRIUMPH-4, the trial built around knee osteoarthritis, has not been published.
- The PubMed abstract prints the 12 mg hybrid-estimand sleep apnoea value without its minus sign, so the per-arm sleep apnoea figures given here are the intention-to-treat ones.
- The abstract does not state at what point in the 80 weeks these two endpoints were measured.
- The abstract does not state the 4 mg arm's differences from placebo for either measure.

### In a phase 2 substudy of 98 participants with MASLD, liver fat fell more with retatrutide than with placebo at 24 weeks.

- Evidence: Human randomised trial. Supportive. Moderate confidence.
- Sources: [6]

Participants in the phase 2 obesity trial who had MASLD (metabolic dysfunction-associated steatotic liver disease) and liver fat of at least 10% were randomised, 98 in all, to retatrutide at 1, 4, 8 or 12 mg, or to placebo. The mean relative change from baseline in liver fat at 24 weeks was -42.9%, -57.0%, -81.4% and -82.4% in the four arms against +0.3% with placebo. Liver fat fell below 5% in 86% of the 12 mg arm and in 0% of the placebo arm.

Caveats:
- Liver fat is a surrogate measure. The study reports nothing about fibrosis, liver histology or clinical liver outcomes.
- 98 participants over 24 weeks, split across five arms.
- The figures come from the published abstract only, which names no estimand.
- The trial was funded by Eli Lilly, the developer.
- The results describe Lilly's investigational product given under trial conditions, not any product sold outside a trial.

## Reported and theoretical risks

### Gastrointestinal adverse events, including diarrhoea and nausea

- Evidence: Human randomised trial. Severity: moderate.
- Sources: [3][1][2][4]

Gastrointestinal events were the most common adverse events in TRIUMPH-1, in the phase 2 obesity trial, which described them as dose-related and mostly mild to moderate, and in TRANSCEND-T2D-1. In TRIUMPH-2, during the trial, diarrhoea occurred in 80 of 292 (27%), 95 of 284 (34%) and 96 of 286 (34%) participants in the 4 mg, 9 mg and 12 mg arms against 38 of 287 (13%) with placebo, and nausea in 40 (14%), 59 (21%) and 80 (28%) against 23 (8%). Permanent discontinuation for adverse events or death was 11 (4%), 33 (12%) and 22 (8%) against 14 (5%) with placebo; that figure combines both causes and is higher at 9 mg than at 12 mg. Over the trial, 6 participants died across the retatrutide arms and 1 on placebo, and the investigator judged every death unrelated to the study intervention. In TRANSCEND-T2D-1, discontinuations due to adverse events were 2 to 5% with retatrutide and 0% with placebo.

### Heart rate increase

- Evidence: Human randomised trial. Severity: unknown.
- Sources: [2]

In the phase 2 obesity trial of 338 adults, heart rate rose in a dose-dependent way, peaked at 24 weeks and declined thereafter. The abstract does not give the size of the increase in beats per minute, so its magnitude cannot be stated here.

### Hypotension

- Evidence: Human randomised trial. Severity: unknown.
- Sources: [3]

In TRIUMPH-2, hypotension was reported in 4 (1%), 14 (5%) and 18 (6%) participants in the 4 mg, 9 mg and 12 mg arms against 1 (<1%) with placebo. The abstract does not describe how severe these events were.

### Dysesthesia

- Evidence: Human randomised trial. Severity: unknown.
- Sources: [3][7]

In TRIUMPH-2, dysesthesia was reported in 13 (4%), 16 (6%) and 21 (7%) participants in the 4 mg, 9 mg and 12 mg arms against 2 (1%) with placebo. A separate pharmacovigilance study, whose database analysis covered other GLP-1 receptor agonists and tirzepatide but not retatrutide, concludes that its data strengthen the evidence for dysesthesia already observed in clinical trials of semaglutide, tirzepatide and retatrutide. Its severity is not stated in the sources used here.

### Products sold as retatrutide did not contain the amount on the label

- Evidence: In-vitro. Severity: unknown.
- Sources: [8]

Three products sold as retatrutide and labelled as containing 10 mg were submitted anonymously for testing in Australia. They contained 5.13 mg (51.3% of the label), 16.5 mg (165.0%) and 19.0 mg (190.0%). That is three products from one country, enough to show the label could not be taken at face value and too few to say how common the problem is.

### Symptoms self-reported online by people using products sold as retatrutide

- Evidence: Anecdotal report. Severity: unknown.
- Sources: [9]

A cross-sectional study of Reddit posts, published in October 2026, found 13,589 users reporting current retatrutide use. The authors excluded weight-loss and appetite-suppression terms in advance. Of the 7,823 users left with at least one symptom mapped, the most reported were increased appetite (17.1%), fatigue (15.2%), increased energy (12.4%), nausea (11.6%) and food craving (7.3%), with insomnia at 6.1% and heart rate increase at 4.8%. The authors state the analysis cannot assess incidence or causality, and that product identity, purity and dose could not be verified.

### Persistent nausea and vomiting after injections of a product reported to contain retatrutide

- Evidence: Human case report. Severity: moderate.
- Sources: [10]

A case report from Zurich, published in October 2026, describes a woman in her mid-20s admitted to hospital with five days of persistent nausea and vomiting after four weekly injections of an unverified product reported to contain retatrutide. No other cause was found, her symptoms resolved within a week, and the authors rated the link as probable. One case, with a product that was not analysed.

## Regulatory status

- US, FDA: not approved (as of 2026-10-01). FDA states that retatrutide is not a component of any FDA-approved drug, that FDA has made no finding of safety and effectiveness for it for any condition, and that it cannot be used in compounding under federal law. Read from FDA's page on unapproved GLP-1 drugs, marked as current on 1 October 2026. [11]
- EU, EMA: not approved (as of 2026-10-02). Neither retatrutide nor LY3437943 has an entry in EMA's register of the medicines it has assessed, in the copy generated on 2 October 2026. That register covers medicines assessed centrally by EMA. It does not cover authorisations granted by a single member state's national agency, so this is not a check of every national register. [12]
- UK, MHRA: not approved (as of 2025-10-24). MHRA describes retatrutide as a medicine in clinical development that has not been approved for UK use, and says that outside authorised clinical trials, products sold in the UK that claim to contain it are likely to be illegal. From a press release of 24 October 2025, read in a browser by a person on 4 October 2026 because gov.uk could not be reached from the environment used to research this page. [13]
- AU, TGA: not approved (as of 2026-09-14). The TGA states that retatrutide is undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator. From a safety advisory of 14 September 2026, read in a browser by a person on 4 October 2026 because tga.gov.au could not be reached from the environment used to research this page. [14]

## Context

Retatrutide is a single synthetic peptide that acts on the receptors for three hormones: GIP, GLP-1 and glucagon. Eli Lilly developed it under the code LY3437943. It is investigational. [FDA states](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) that it is not a component of any FDA-approved drug, and it has no entry in the register of medicines EMA has assessed.

## What it is

The molecule is not a plain chain of the twenty amino acids the genetic code specifies. [FDA's substance record](https://precision.fda.gov/ginas/app/ui/substances/NOP2Y096GV) describes 2-methylalanine at two positions and 2-methyl-L-leucine at a third, neither of them a coded amino acid, together with a C-terminal amide and a 20-carbon fatty diacid attached to a lysine side chain through a linker. No sequence written in the twenty standard one-letter codes can describe that structure, which is why none is shown on this page.

The same FDA record also prints a one-letter backbone string, but that string writes the modified residues as ordinary ones and leaves out the fatty-acid chain, and the record flags the weight it calculates from it as a fallback. The molecular weight given here, 4731, is the figure that matches the full structure.

## Where the evidence stands

Three phase 3 trials have been published, all funded by Eli Lilly and all against placebo. [TRIUMPH-1](https://pubmed.ncbi.nlm.nih.gov/42814954/) studied adults with obesity and without diabetes, and [TRIUMPH-2](https://pubmed.ncbi.nlm.nih.gov/42810372/) adults with type 2 diabetes and a BMI of 27 or higher. Both ran for 80 weeks and both were published on 29 September 2026. [TRANSCEND-T2D-1](https://pubmed.ncbi.nlm.nih.gov/42250575/), a 40-week trial in type 2 diabetes, was published in June 2026. They follow phase 2 trials in [obesity](https://pubmed.ncbi.nlm.nih.gov/37366315/) and [type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/37385280/). The figures on this page come from the published abstracts; the full texts were not available when it was written.

Two further phase 3 trials, [TRIUMPH-3](https://clinicaltrials.gov/study/NCT05882045) and [TRIUMPH-4](https://clinicaltrials.gov/study/NCT05931367), are recorded as completed on ClinicalTrials.gov and had not been published in a journal when this page was written. No figure from either appears here.

Several things do not exist yet. Eighty weeks is the longest treatment period published. No trial comparing retatrutide with tirzepatide has reported: [TRIUMPH-5](https://clinicaltrials.gov/study/NCT06662383), which compares the two, has an estimated primary completion of November 2026. A trial against semaglutide in type 2 diabetes, [TRANSCEND-T2D-2](https://clinicaltrials.gov/study/NCT06260722), records an actual primary completion in August 2026 and has posted no results. No peer-reviewed publication reports cardiovascular or kidney outcomes. The trial built to measure them, [TRIUMPH-Outcomes](https://clinicaltrials.gov/study/NCT06383390), has an estimated primary completion of February 2029.

Lilly runs a [pre-approval expanded access programme](https://clinicaltrials.gov/study/NCT07629401) for retatrutide, first posted on 5 June 2026. It is for individual adults with obesity that has not responded to the highest available dose of existing weight management treatment, a BMI of 35 or more and at least two serious or life-threatening obesity-related complications, who cannot join a trial. That is not an approval.

## What is sold online has not been shown to be the trial drug

Retatrutide is sold online by companies that label it for research use. FDA has named it in warning letters since its [17 December 2024 roundup](https://www.fda.gov/news-events/press-announcements/fda-roundup-december-17-2024), which announced four letters to companies for introducing unapproved GLP-1 products, among them semaglutide, tirzepatide and retatrutide in some combination, into interstate commerce. The letters reject the research label. In a [March 2026 warning letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026), FDA said that despite "Research Use Only" statements on the labelling, "evidence obtained from your website establishes that your products are intended to be drugs for human use". It made the same finding in [another letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026) in August 2026. FDA also states that retatrutide cannot be used in compounding under federal law.

What these products contain is a separate question, and the evidence on it is thin. One [published analysis](https://pubmed.ncbi.nlm.nih.gov/42559975/) tested three products sold as retatrutide in Australia, each labelled as containing 10 mg, and measured from roughly half to almost double that amount. All three did contain retatrutide, judged by molecular weight; what failed was the quantity, not the identity. The [TGA tested a fourth product](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/tga-tests-counterfeit-retatrutide-product-following-serious-adverse-event-report), sold as retatrutide and linked to a report of a serious adverse effect, and found undeclared semaglutide and no retatrutide; that advisory was read in a browser by a person, because the TGA's website could not be reached from the environment used to research this page. Four products from one country cannot show how common either problem is. The [regulatory status page](/articles/is-retatrutide-fda-approved/) sets out what regulators have found.

What happens to the people using them is documented even more thinly. A [study of Reddit posts](https://pubmed.ncbi.nlm.nih.gov/42873503/) published in October 2026 identified 13,589 users who reported current retatrutide use between March 2023 and December 2025, and used a language model to extract the symptoms they described. After weight-loss and appetite-suppression terms were excluded in advance, increased appetite, fatigue, increased energy and nausea were the most reported, and insomnia and heart rate increase also appeared. The authors say the analysis cannot assess incidence or causality, that what users actually injected could not be verified, and that the findings are hypothesis-generating. A [case report from Zurich](https://pubmed.ncbi.nlm.nih.gov/42843917/) describes a woman in her mid-20s admitted to hospital with persistent nausea and vomiting after injections of an unverified product reported to contain retatrutide, given in a wellness setting by a life coach without medical qualification. Her symptoms resolved within a week.

Every trial result on this page describes Lilly's investigational product given under trial conditions. None of it describes a product bought online.

## Anti-doping

WADA's Prohibited List could not be retrieved for this page, so the page says nothing about retatrutide's status in sport, in either direction.

## Sources

1. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. https://doi.org/10.1056/NEJMoa2604169
2. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023. https://doi.org/10.1056/NEJMoa2301972
3. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026. https://doi.org/10.1016/S0140-6736(26)01861-1
4. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026. https://doi.org/10.1016/S0140-6736(26)00967-0
5. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023. https://doi.org/10.1016/S0140-6736(23)01053-X
6. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. https://doi.org/10.1038/s41591-024-03018-2
7. Laroche ML, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026. https://doi.org/10.1007/s00228-026-04079-7
8. Piatkowski T et al. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review. 2026. https://doi.org/10.1111/dar.70231
9. Sehgal NKR et al. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open. 2026. https://doi.org/10.1001/jamanetworkopen.2026.38929
10. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Reports. 2026. https://doi.org/10.1136/bcr-2026-276106
11. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
12. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026. https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx
13. MHRA smashes major illicit weight loss medicine production facility in record seizure. Medicines and Healthcare products Regulatory Agency. 2025. https://www.gov.uk/government/news/mhra-smashes-majorillicitweight-loss-medicine-production-facility-in-record-seizure
14. TGA tests counterfeit retatrutide product following serious adverse event report. Therapeutic Goods Administration. 2026. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/tga-tests-counterfeit-retatrutide-product-following-serious-adverse-event-report
